Tromboliticheskaya terapiya pri ishemicheskom insul'te: prediktory bezopasnosti i effektivnosti


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

A systemic thrombolytic therapy with account of clinical and pathogenetic features of the disease, localization of the lesion, results of additional methods of diagnosis (primarily neuroimaging), identification of predictors for bleeding complications will contribute to safer and more effective use of this method for the treatment of patients with ischemic stroke.

Full Text

Restricted Access

References

  1. http: //www.eso-stroke.org
  2. Jauch E.C., Saver J.L., Adams HP Jr., et al.; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology.Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2013; 44: 870-947.
  3. Del Zoppo G.J., Zeumer H., Harker L.A. Thrombolytic therapy in acute stroke: Possibilities and hazards. Stroke 1986; 17: 595-607.
  4. Solis O.J., Roberson G.R., Taveras J.M., et al. Cerebral angiography in acute cerebral infarction. Revist Interam Radiol 1977; 2: 19-25.
  5. Matsuo O., Kosugi T., Mihara H., et al. Retrospective study on the efficacy of using urokinase therapy. Acta Haem Jap 1979; 42: 684-88.
  6. The Multicentre Acute Stroke Trial - Italy (Mast-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet. 1995; 346(8989): 1509-14.
  7. The Multicentre Acute Stroke Trial -Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N. Engl. J. Med. 1996; 335(3): 145-50.
  8. Yasaka M., Chambers B.R., Davis S.M., Donnan G.A. Streptokinase in acute stroke: effect on reperfusion and recanalization. Australian Streptokinase Trial Study Group. Neurology. 1998; 50(3): 626-32.
  9. Инструкция к препарату «Алтеплаза». http://www.boehringer-ingelheim.ru/content/dam/internet/opu/ru_RU/documents/PM%20new/Actilyse%2020.02.2013.pdf.
  10. Tanswell P., Tebbe U., Neuhaus K.-L., et al. Pharmacokinetics and fibrin specificity of Alteplase during accelerated infusions in acute myocardial infarction. J. Am. Coll. Cardiol. 1992; 19: 1071-75.
  11. Brott T.G., Haley E.C. Jr, Levy D.E., et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23: 632-40.
  12. Haley E.C. Jr, Levy D.E., Brott T.G., et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23: 641-45.
  13. Tissue Plasminogen Activator For Acute Ishemic Stroke. N. Engl. J. Med. 1995; 333(24).
  14. Hacke W., Kaste M., Fieschi C., et al.; for the ECASS Study Group. Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274(13).
  15. Hacke W., Kaste M., Fieschi C., et al.; for the Second European-Australasian Acute Stroke Study Investigators. Randomised doubleblind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998; 352(Issue 9136): 1245-51.
  16. Clark W.M., Wissman S., Albers G.W., et al.; for the ATLANTIS Study Investigators. Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset. The ATLANTIS Study: A Randomized Controlled Trial. JAMA. 1999; 282: 2019-26.
  17. Hacke W., Kaste M., Bluhmki E., et al.; for the ECASS Investigators. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. N. Eng.l J. Med. 2008; 359: 131729.
  18. The IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012; 379(Issue 9834): 2352-63.
  19. The ATLANTIS, ECASS, AND NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004; 363: 768-74.
  20. Bray B.D., Campbell J., Cloud G.C., et al. On behalf of the Intercollegiate Stroke Working Party Group. Bigger, Faster? Associations Between Hospital Thrombolysis Volume and Speed of Thrombolysis Administration in Acute Ischemic Stroke. Stroke. 2013; 44: 3129-35.
  21. Carlson M.D., Leber S., Deveikis J., Silverstein F.S. Successful use of rt-PA in pediatric stroke. Neurology. 2001; 57: 157-58.
  22. Engelter S.T., Bonati L.H., Lyrer P.A. Intravenous thrombolysis in stroke patients of 80 versus 80 years of age-a systematic review across cohort studies. Age Ageing 2006; 35: 572-80.
  23. Mateen Farrah J., Buchan Alastair M., Michael D. Hill on behalf of the CASES Investigators, Outcomes of Thrombolysis for Acute Ischemic Stroke in Octogenarians Versus Nonagenarians. Stroke. 2010; 41: 1833-35.
  24. Khaw K.T., Barrett-Connor E., Suarez L., Criqui M.H. Predictors of stroke associated mortality in the elderly. Stroke. 1984; 15: 244-48.
  25. Wardlaw J.M., Murray V., Berge E., del Zoppo G.J. Thrombolysis for Acute Ischemic Stroke. Stroke 2010; 41; e445-46.
  26. Anzini A., Niaz A., Durastanti L., et al. Thrombolysis in young patients: the SITSMOST data. Cerebrovasc. Dis. 2008; 25(suppl 2): 3.
  27. Putaala J., Metso M., Metso A.J., et al. Thrombolysis in Young Adults With Ischemic Stroke, Stroke 2009; 40; 2085-91.
  28. Pessin M., del Zoppo G.J., Estol C. Thtombolytic agents in the treatment of stroke. Clin. Neuropharmacol. 1990; 13; 271 -89.
  29. Okada Y., Yamaguchi T., Minematsu K., et al. Hemorrhagic transformation in cerebral embolism. Stroke, May 1989; 20: 598-603.
  30. Lodder J., Krijne-Kubat B., and Broekman J. Cerebral hemorrhagic infarction at autopsy: cardiac embolic cause and the relationship to the cause of death. Stroke. 1986; 17: 626-29.
  31. NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997; 28: 2119-25.
  32. Fiorelly M., Bastianello S., von Kummer R., et al.; for the ECASS I Study Group. Hemorrhagic transformation within 36 hours of a cerebral infarct. Relationship with early clinical deterioration and 3-month outcome in the ECASS I cohort. Stroke. 1999; 30: 2280-84.
  33. Neumann-Haefelin Tobias, Silke Hoelig; Joachim Berkefeld, et al.; for the MR Stroke Group. Leukoaraiosis Is a Risk Factor for Symptomatic Intracerebral Hemorrhage After Thrombolysis for Acute Stroke. Stroke. 2006; 37: 2463-66.
  34. Dubey N., Bakshi R., Wasay M., Dmochowski J. Early computed tomography hypodensity predicts hemorrhage after intravenous tissue plasminogen activator in acute ischemic stroke. J. Neuroimaging. 2001; 11: 184-88.
  35. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The National Institute of Neurological Disorders and Stroke Study Group. Stroke. 1997; 28: 2109-18.
  36. Barber P.A., Demchuk A.M., Zhang J., Buchan A.M. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet. 2000; 355: 1670-74.
  37. Dzialowski I., Hill D., Shelagh B. Coutts, et al. Extent of Early Ischemic Changes on Computed Tomography (CT) Before Thrombolysis: Prognostic Value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke. 2006; 37: 973-78.
  38. Lindsberg P.J., Happola O., Kallela M., et al. Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment, Neurology. 2006; 67; 334-36.
  39. Martin-Schild S., Morales M.M., Khaja A.M., et al. Is the drip-and-ship approach to delivering thrombolysis for acute ischemic stroke safe? J. Emerg. Med. 2009; 41(2): 135-41.
  40. Mayer T.E., Hamann G.F., Brueckmann H.J. Treatment of basilar artery embolism with a mechanical extraction device: Necessity of flow reversal. Stroke. 2002; 33: 2232-35.
  41. Schonewille W.J., Wijman C.A., Michel P., et al. Treatment and outcomes of acute basilar artery occlusion in the basilar artery international cooperation study (basics): A prospective registry study. Lancet Neurol. 2009; 8: 724-30.
  42. Silverman I.E., Beland D.K., Chhabra J., McCullough L.D. The «Drip-and-ship» Approach: Starting iv t-pa for acute ischemic stroke at outside hospitals prior to transfer to a regional stroke center. Conn. Med. 2005; 69: 613-20.
  43. Pfefferkorn T., Mayer T.E., Opherk C., et al. Staged escalation therapy in acute basilar artery occlusion: Intravenous thrombolysis and on-demand consecutive endovascular mechanical thrombectomy: Preliminary experience in 16 patients. Stroke. 2008; 39: 1496-500.
  44. Pfefferkorn T., Holtmannspotter M., Schmidt C., et al. Drip, ship, and retrieve: Cooperative recanalization therapy in acute basilar artery occlusion. Stroke. 2010; 41: 722-26.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies